OBJECTIVE: Insulin degradation pathways may be related to Alzheimer's disease pathology. In preliminary analyses, we considered the relation of combined lower insulin secretion (c-peptide) and higher insulin--possibly a phenotype for impaired insulin degradation--to cognitive decline. METHOD: Fasting plasma c-peptide and insulin were measured in 1,187 non-diabetic Nurses' Health Study participants (mean age = 64 years). Cognitive testing began 10 years later. Participants completed three repeated assessments (over an average span of 4.4 years) of verbal memory, a strong predictor of Alzheimer disease development. C-peptide and insulin distributions were dichotomized at their medians to create four cross-tabulated categories. Multivariable linear mixed effects models were used to relate c-peptide/insulin categories to cognitive decline. RESULTS: Compared to the lower c-peptide/lower insulin group, women with lower c-peptide/higher insulin had a significantly faster rate of verbal memory decline: the mean difference was -0.05 units/year (95% CI -0.09,-0.01). This mean difference was similar to that which we found for women 5 years apart in age, indicating that having a profile of lower c-peptide/higher insulin appeared cognitively equivalent to aging by five years on tests of verbal memory. For women with higher c-peptide/higher insulin, the estimated mean difference in decline compared to those in the lower c-peptide/lower insulin group was statistically significant, but slightly lower, at -0.04 units/year (95% CI: -0.07,-0.02). CONCLUSION: These preliminary analyses of a possible phenotype of impaired insulin degradation provide supportive evidence that deficits in insulin degradation may be related to late-life verbal memory decline. (c) 2008 John Wiley & Sons, Ltd.
OBJECTIVE:Insulin degradation pathways may be related to Alzheimer's disease pathology. In preliminary analyses, we considered the relation of combined lower insulin secretion (c-peptide) and higher insulin--possibly a phenotype for impaired insulin degradation--to cognitive decline. METHOD: Fasting plasma c-peptide and insulin were measured in 1,187 non-diabetic Nurses' Health Study participants (mean age = 64 years). Cognitive testing began 10 years later. Participants completed three repeated assessments (over an average span of 4.4 years) of verbal memory, a strong predictor of Alzheimer disease development. C-peptide and insulin distributions were dichotomized at their medians to create four cross-tabulated categories. Multivariable linear mixed effects models were used to relate c-peptide/insulin categories to cognitive decline. RESULTS: Compared to the lower c-peptide/lower insulin group, women with lower c-peptide/higher insulin had a significantly faster rate of verbal memory decline: the mean difference was -0.05 units/year (95% CI -0.09,-0.01). This mean difference was similar to that which we found for women 5 years apart in age, indicating that having a profile of lower c-peptide/higher insulin appeared cognitively equivalent to aging by five years on tests of verbal memory. For women with higher c-peptide/higher insulin, the estimated mean difference in decline compared to those in the lower c-peptide/lower insulin group was statistically significant, but slightly lower, at -0.04 units/year (95% CI: -0.07,-0.02). CONCLUSION: These preliminary analyses of a possible phenotype of impaired insulin degradation provide supportive evidence that deficits in insulin degradation may be related to late-life verbal memory decline. (c) 2008 John Wiley & Sons, Ltd.
Authors: Wesley Farris; Stefan Mansourian; Yang Chang; Loren Lindsley; Elizabeth A Eckman; Matthew P Frosch; Christopher B Eckman; Rudolph E Tanzi; Dennis J Selkoe; Suzanne Guenette Journal: Proc Natl Acad Sci U S A Date: 2003-03-12 Impact factor: 11.205
Authors: O K Faber; C Binder; J Markussen; L G Heding; V K Naithani; H Kuzuya; P Blix; D L Horwitz; A H Rubenstein Journal: Diabetes Date: 1978 Impact factor: 9.461
Authors: Sid E O'Bryant; Guanghua Xiao; Fan Zhang; Melissa Edwards; Dwight C German; Xiangling Yin; Tori Como; Joan Reisch; Ryan M Huebinger; Neill Graff-Radford; Dennis Dickson; Robert Barber; James Hall; Padraig O'Suilleabhain; Paula Grammas Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472
Authors: Sid E O'Bryant; Guanghua Xiao; Robert Barber; Joan Reisch; James Hall; C Munro Cullum; Rachelle Doody; Thomas Fairchild; Perrie Adams; Kirk Wilhelmsen; Ramon Diaz-Arrastia Journal: Dement Geriatr Cogn Disord Date: 2011-08-24 Impact factor: 2.959
Authors: G Peggy McFall; Sandra A Wiebe; David Vergote; David Westaway; Jack Jhamandas; Roger A Dixon Journal: Neurobiol Aging Date: 2013-04-16 Impact factor: 4.673
Authors: Anne Corbett; James Pickett; Alistair Burns; Jonathan Corcoran; Stephen B Dunnett; Paul Edison; Jim J Hagan; Clive Holmes; Emma Jones; Cornelius Katona; Ian Kearns; Patrick Kehoe; Amrit Mudher; Anthony Passmore; Nicola Shepherd; Frank Walsh; Clive Ballard Journal: Nat Rev Drug Discov Date: 2012-11 Impact factor: 84.694
Authors: Brenna Cholerton; Laura D Baker; Emily H Trittschuh; Paul K Crane; Eric B Larson; Matthew Arbuckle; Hector Hernandez Saucedo; Susan M McCurry; James D Bowen; Wayne C McCormick; Suzanne Craft Journal: J Alzheimers Dis Date: 2012 Impact factor: 4.472
Authors: Grazia Daniela Femminella; Eleni Frangou; Sharon B Love; Gail Busza; Clive Holmes; Craig Ritchie; Robert Lawrence; Brady McFarlane; George Tadros; Basil H Ridha; Carol Bannister; Zuzana Walker; Hilary Archer; Elizabeth Coulthard; Ben R Underwood; Aparna Prasanna; Paul Koranteng; Salman Karim; Kehinde Junaid; Bernadette McGuinness; Ramin Nilforooshan; Ajay Macharouthu; Andrew Donaldson; Simon Thacker; Gregor Russell; Naghma Malik; Vandana Mate; Lucy Knight; Sajeev Kshemendran; John Harrison; Christian Hölscher; David J Brooks; Anthony Peter Passmore; Clive Ballard; Paul Edison Journal: Trials Date: 2019-04-03 Impact factor: 2.279